COMPANY PROFILE

OncoC4

Request full access

North Potomac, United StatesFounded 2020Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

At a glance

Status: Operational
Founded: 2020
Headquarters: North Potomac, United States
Employees: 69
Open positions: None listed
Dealroom signal: 42.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Investment activity: 1 company, latest Sep 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Founder mafias, market maps, lists and research connected to this company by Dealroom

Market maps in Biotech & Life Sciences

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Oct 2025	$50M	$200M	Kaitai Capital · HM Capital · Yang Liu · 3E Bioventures	↗

OncoC4 website traffic

Latest recorded traffic for OncoC4 is 3.4K monthly website visits, down 44.3% over the last three months. OncoC4's team grew 1.5% over the past year.

Latest monthly visits3.4K 3-month web change-44.3% 1-year team growth+1.5%

Monthly website visitsApr 2021–Jul 2026

Summary metrics are public; monthly history is available with a demoCompare with peers →

Openings linked to this company in Dealroom

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed	—	$1.1M	$4.4M
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed